Navigation Links
Bioniche Reports Fiscal 2008 Third Quarter
Date:5/9/2008

-----------------------------------------------------

4,345,479 4,373,099 13,140,813 13,152,822

-------------------------------------------------------------------------

Loss before research

and development

expenses and other

items (192,819) (647,651) (1,735,590) (1,706,600)

Research and

development

expenses, gross 4,416,249 4,199,003 11,646,663 11,350,443

Less: government

incentives, net (250,659) (425,667) (969,242) (1,262,201)

Change in

unrealized loss on

foreign currency

embedded

derivatives 191,096 - 52,893 -

Impairment of

investment - - - 175,000

Loss on sale of

investment - - - 17,157

Gain on sale of

right to future

royalty stream - - - (2,127,587)

-------------------------------------------------------------------------

Loss before income

taxes (4,549,505) (4,420,987) (12,465,904) (9,859,412)

Provision for

income taxes 92,805 89,447 206,329 304,957

-------------------------------------------------------------------------

Net loss for the

period (4,642,310) (4,510,434) (12,672,233) (10,164,369)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and diluted

net loss per share (0.07) (0.10) (0.20) (0.25)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted-average

nu
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Bioniche Appoints U.S. President of Food Safety
2. Bioniche Reports the Passing of its Board Chair
3. Bioniche Converts a Portion of its Debt to Equity
4. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
5. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
6. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
7. Bioniche Reports Fiscal 2008 Second Quarter
8. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
11. Bioniche Reports Fiscal 2008 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)... EVANSTON, Ill., May 9 /PRNewswire-USNewswire/ -... effort to help relieve the unspeakable human,suff...ecial donation kiosks,have been developed and are ...ual world of Second Life, with coordination being ... main island,( http://slurl.com/secondlife/Simuali...
(Date:5/9/2008)... Coalition for Iraq and Afghanistan Veterans Gat...tary & Veterans Service Organizations,, CHANTI...war in Iraq,enters its fifth year and the U.S. dea...proach the 30,000 mark, a diverse coalition of mil...mefront have organized to help,bereaved families a...
(Date:5/9/2008)...cientists find disease-resistant gene wards off fu...(HealthDay News) -- A molecular-based approach to ...as been identified by Dutch scientists. , In ag...bility of plant pathogens to co-evolve along with ...kground information in the study. One way to incre...
(Date:5/9/2008)...ntellectual demands reap mental benefits regardles...RIDAY, May 9 (HealthDay News) -- Having an intelle...ties may result in better cognitive abilities duri...on level or age, a Duke University Medical Center ...ive and work longer than previous generations, so ...
Breaking Medicine News(10 mins):Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Demanding Jobs May Pay Cognitive Dividends in Retirement 2
...nese scientists have announced that they are stari... that has proved to be useful for both HIV/AIDS as...oylquinic acid (1,5-DCQA),// is an extract from a ...n HIV as well as HBV, according to Dong Junxing, a...
...women demand epidurals during delivery even if not...atest demand of midwives through the experts at Ro... would help stem the// growing number of women ask...nt women in the UK have an epidural, which costs a...
...erbarium will be set up in Jharkhand to preserve t...inction. The government has tied up with yoga guru... Research Institute (TRI) in the state will set up... an initial investment of Rs.150,000. Baba Ramdev'...
...ton - Make no bones about it – For those troubled ...ncrete about it. According to a study, Amgen Inc.'...an rejuvenate the density of bones present in the ...dicine has reported the effect of this drug after ...
Other Medicine News:
(Date:5/9/2008)... TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Ost...ing condition that affects almost 50,million peopl...ion of,cartilage in bone joints. The novel investi...cting oral analgesic, provided significant relief,...those treated with,placebo, and with fewer gastroi...
(Date:5/9/2008)... SAN DIEGO, May 9 /- Ardea...used on the discovery and development of,small- mo...er and,inflammatory diseases, including gout, toda...enior Vice President, Finance and Operations and C...will resign from our board of,directors shortly th...
(Date:5/8/2008)... CLEVELAND, May 8 /- DATAT...logy and services company focused on global,eClini...day reported its,operating results for the first q... 31, 2008, revenue decreased,approximately 41% to ...$(2,233,000), or $(0.16) per share on both a basic...
(Date:5/8/2008)...ficacy and safety data support potential of asenap...enia and bipolar I disorder, WASHINGTON, May 8 /P...n,(NYSE: SGP ) today announced that an overview o...am was presented at the 161st Annual Meeting of th...D.C., May 3-8. Data from,the studies, involving pa...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Team demos safety of RNA therapy 883 1Team demos safety of RNA therapy 883 2Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano 882 1Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano 882 2Doping technique brings nanomechanical devices into the semiconductor world 880 1Doping technique brings nanomechanical devices into the semiconductor world 880 2Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 1Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 2Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 3Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 4Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 5Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 6Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 7Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 8Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 9Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2157 10
Automated Cortisol assay with flexible sample types for increased laboratory workflow, Excellent correlation and agreement with commercial Cortisol assay provides confidence,in assay performanc
Rapid assay, results in 1 hours,Assay sensitivity of 1.14 ng/mL
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
... from KUBTEC is a dual capability system with the ...sentation of the specimen under test. While the XC...ecimen X-ray images, the micro focus source also a...n standard 2D images. The 100 mm x 100 mm digital ...
Medicine Products: